Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs through Process Engineering and Technological Innovation

PDF 145 kB

This case study presents the successful collaboration between an early-stage company that was struggling with the development of a realistic and economically viable commercial pathway and BioVectra, a CDMO with 50 years of experience.

Content provided by our supplier

BioVectra Inc.

Country/Region:

Canada
On CPHI since:

2015
Certificates:

2
Employees:

500 - 999

Company types

CMO/CDMO

Primary activities

Biopharmaceutical

Contact info

+1 902 566 9116
Website
11 Aviation Ave, C1E 0A1, Charlottetown, PE, Canada

Other Content from BioVectra Inc. (4)

Video BioVectra's CDMO Capabilities

BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients (APIs) from five North American cGMP facilities. We specialize in Microbial Fermentation, Complex Chemistry, Biologics, and Formulation Development.

2020-10-06
Brochure BIOVECTRA Company Overview

Learn more about BIOVECTRA in this company overview.
Whitepaper An Innovative Approach to Manufacturing Biologics using Microbial Fermentation

This Whitepaper outlines what a platform technology is and how it can speed up process development, the impact of high-throughput technologies, and what single-use, disposable technologies are currently on the market for biologics manufacturing.
Whitepaper Supporting Client Projects for CDMO Success

The production of increasingly complex small molecule APIs is challenging. CDMOs with multiple capabilities are needed to develop efficient routes to synthesize these complicated molecules. This paper outlines how BioVectra supports client projects.